Glaukos reported FY 2025 net sales of USD 507.44 million (+32%), with gross margin of 56% and a net loss of USD 187.69 million (+28%). Operating expenses totaled USD 482.36 million (+17%), including SG&A of USD 331.75 million (+27%) and R&D of USD 150.61 million (+10%); loss from operations was USD 199.60 million (+63%). Cash, cash equivalents, short-term investments and restricted cash were USD 282.59 million at December 31, 2025. In business updates, Glaukos said the U.S. FDA approved Epioxa for keratoconus on October 20, 2025, with commercialization planned for Q1 2026; the company recorded a USD 112.9 million impairment charge in cost of sales related to its Photrexa developed technology intangible asset. Glaukos also received EU MDR certification in June 2025 for its iStent family (including iStent infinite and iStent inject W) and began some commercial launch activities in key EU markets in Q3 and Q4 2025. The company acquired Mobius Therapeutics on May 16, 2025 for USD 12.4 million (net of cash acquired), adding Mitosol, and purchased an adjacent Aliso Viejo building on April 4, 2025 for USD 16.6 million; it also said it expects construction to begin in 2026 on a planned 200,000 square foot Huntsville, Alabama R&D and manufacturing facility anticipated to result in more than USD 80 million in capital expenditures over a multi-year project.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-061944), on February 23, 2026, and is solely responsible for the information contained therein.